Coya Therapeutics (Coya Therapeutics) Pre-Tax Income : $-9.58 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Coya Therapeutics's pretax income for the three months ended in Mar. 2024 was $-5.05 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.58 Mil. Coya Therapeutics's pretax margin was -3,977.95%.

During the past 4 years, Coya Therapeutics's highest Pretax Margin was -121.03%. The lowest was -156.29%. And the median was -121.03%.

Coya Therapeutics Pre-Tax Income Historical Data

The historical data trend for Coya Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics Pre-Tax Income Chart

Coya Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-4.89

-12.25

-7.26

Coya Therapeutics Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial						-2.74	-3.10	-3.42	1.99	-5.05

Competitive Comparison of Coya Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Coya Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coya Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's Pre-Tax Income falls into.

Coya Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Coya Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-7.36	+	0.096	+	0	+	0	+	0
	=	-7.26

Coya Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-5.458	+	0.406	+	0	+	0	+	8.8817841970013E-16
	=	-5.05

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.58 Mil.

Coya Therapeutics (NAS:COYA) Pre-Tax Income Explanation

Coya Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-5.052	/	0.127
	=	-3,977.95%

During the past 4 years, Coya Therapeutics's highest Pretax Margin was -121.03%. The lowest was -156.29%. And the median was -121.03%.

Coya Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Coya Therapeutics (Coya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057

Website

https://www.coyatherapeutics.com

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Executives

Dieter Weinand	director	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Fred Grossman	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Goldstein Dov A Md	director
Adrian Hepner	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
David S Snyder	officer: Chief Financial Officer	ONE SCIENCE COURT, MADISON WI 53711
Hideki Garren	director	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman	director, 10 percent owner, officer: Chief Executive Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc	10 percent owner	5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057